Metagenomi Therapeutics ($MGX) $7.5 Million Investor Settlement
Metagenomi Therapeutics agreed to a $7.5 million settlement resolving claims that its IPO materials misled investors about the status and progress of its collaboration with Moderna.
Outline:
Metagenomi completed its initial public offering in February 2024 at $15 per share. Investors allege that the company’s IPO materials contained misleading statements and omissions about its collaboration with Moderna. The lawsuit claims investors were not given an accurate picture of the status and progress of the collaboration’s preclinical programs. Metagenomi and the individual defendants have agreed to resolve the claims for $7.5 million.
Timeline:
January 5, 2024: Metagenomi filed the registration statement used for its initial public offering.
February 9, 2024: Metagenomi common stock began trading on Nasdaq under the ticker MGX at an IPO price of $15 per share.
February 12, 2024: Metagenomi filed the prospectus used in connection with its IPO.
February 13, 2024: Metagenomi completed its IPO, through which 6.25 million shares were issued and sold.
September 26, 2024: Investors filed a securities lawsuit alleging that Metagenomi’s IPO materials contained misleading statements and omissions.
November 18, 2026: The parties entered into a formal $7.5 million settlement agreement.
Background:
Metagenomi is a biotechnology company that completed its initial public offering in February 2024. The company issued 6.25 million shares at $15 per share, with its common stock beginning to trade on Nasdaq under the ticker MGX.
The company’s IPO registration statement discussed Metagenomi’s collaboration with Moderna and the progress of preclinical programs being developed through that relationship. Investors later alleged that those disclosures did not accurately describe the status of the collaboration and omitted material information about the progress of the programs.
The lawsuit alleges that investors purchased Metagenomi shares based on IPO materials containing untrue statements or material omissions. The claims were brought under Sections 11 and 15 of the Securities Act of 1933 and did not allege fraud, recklessness, or intentional misconduct.
In March 2026, the Court allowed certain claims concerning statements and omissions about the Moderna collaboration to proceed. The parties later entered mediation and reached an agreement in principle on October 21, 2026.
What Can Investors Expect Now?
Metagenomi Therapeutics agreed to a $7.5 million settlement resolving claims that its IPO materials misled investors about the status and progress of its collaboration with Moderna.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Frequently Asked Questions
All persons and entities that purchased or otherwise acquired Metagenomi common stock pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the IPO, and were damaged thereby.
</answer>
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.